Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China , Clearing the Path…